1h Free Analyst Time
The motion sickness drugs market is forecasted to grow by USD 139.5 million during 2023-2028, accelerating at a CAGR of 4.37% during the forecast period. The report on the motion sickness drugs market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.Speak directly to the analyst to clarify any post sales queries you may have.
The report offers an up-to-date analysis regarding the current market scenario, the latest trends and drivers, and the overall market environment. The market is driven by availability of over-the-counter (otc) drugs, availability of motion sickness drugs in multiple dosage forms, and growing travel and tourism worldwide.
The motion sickness drugs market is segmented as below:
By Product
- Antihistamines
- Anticholinergics
By Distribution Channel
- Offline
- Online
By Geography
- North America
- Europe
- Asia
- Rest of World (ROW)
The report on the motion sickness drugs market covers the following areas:
- Motion sickness drugs market sizing
- Motion sickness drugs market forecast
- Motion sickness drugs market industry analysis
The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to an analysis of the key vendors.
The report presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive research - both primary and secondary. The market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast the accurate market growth.
Table of Contents
1 Executive Summary
2 Market Landscape
3 Market Sizing
4 Historic Market Size
5 Five Forces Analysis
6 Market Segmentation by Product
7 Market Segmentation by Distribution Channel
8 Customer Landscape
9 Geographic Landscape
10 Drivers, Challenges, and Opportunity/Restraints
11 Competitive Landscape
12 Competitive Analysis
13 Appendix
List of Exhibits
Executive Summary
The following companies are recognized as the key players in the global motion sickness drugs market: Abbott Laboratories, Amneal Pharmaceuticals Inc., Baxter International Inc., CVS Health Corp., DM Pharma Marketing Pvt. Ltd., GlaxoSmithKline Plc, Hylands, Lupin Ltd., Merck KGaA, Myungmoon Pharm Co. Ltd., Novartis AG, Perrigo Co. Plc, Prestige Consumer Healthcare Inc., Sun Pharmaceutical Industries Ltd., Teva Pharmaceutical Industries Ltd., Tivic Health Systems Inc., Viatris Inc., WellSpring Pharmaceutical Corp., Zenomed Healthcare Pvt. Ltd., and Zydus Lifesciences Ltd..Commenting on the report, an analyst from the research team said: "The latest trend gaining momentum in the market is advent of nauseogenic information technology."
According to the report, one of the major drivers for this market is the availability of over-the-counter (otc) drugs.
The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Abbott Laboratories
- Amneal Pharmaceuticals Inc.
- Baxter International Inc.
- CVS Health Corp.
- DM Pharma Marketing Pvt. Ltd.
- GlaxoSmithKline Plc
- Hylands
- Lupin Ltd.
- Merck KGaA
- Myungmoon Pharm Co. Ltd.
- Novartis AG
- Perrigo Co. Plc
- Prestige Consumer Healthcare Inc.
- Sun Pharmaceutical Industries Ltd.
- Teva Pharmaceutical Industries Ltd.
- Tivic Health Systems Inc.
- Viatris Inc.
- WellSpring Pharmaceutical Corp.
- Zenomed Healthcare Pvt. Ltd.
- Zydus Lifesciences Ltd.
